Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression during first-line cetuximab-based therapy.

Authors

Ying Liu

Department of Oncology, Henan Cancer Hospital, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, China

Ying Liu , Feng Wang , Ning Ma , Shuning Xu , Lei Qiao , Ke Li , Gaizhen Kuang , Danyang Li , Yangyang Liu , Yanyan Xiong , Mingming Sun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC).

First Author: Howard S. Hochster

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.

First Author: Yijiao Chen

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens.

First Author: Arthur C. Houts

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer—A GERCOR Study.

First Author: Benoist Chibaudel